Search Results - "Boucher, Helen W."

Epidemiology of Methicillin-Resistant Staphylococcus aureus by Boucher, Helen W., Corey, G. Ralph

“…The frequency of methicillin-resistant Staphylococcus aureus (MRSA) infections continues to grow in hospital-associated settings and, more recently, in…”
Get full text

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America by Boucher, Helen W., Talbot, George H., Bradley, John S., Edwards, John E., Gilbert, David, Rice, Louis B., Scheld, Michael, Spellberg, Brad, Bartlett, John

“…The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections,…”
Get full text

Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-Resistant Staphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci by Rivera, Ana Maria, MD, Boucher, Helen W., MD

“…Gram-positive bacteria cause a broad spectrum of disease in immunocompetent and immunocompromised hosts. Despite increasing knowledge about resistance…”
Get full text

Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus by Boucher, Helen W., Sakoulas, George

“…Methicillin-resistant Staphylococcus aureus infections are becoming more frequent and less easily treated by means of currently recommended agents. Vancomycin…”
Get full text

Challenges in Anti-Infective Development in the Era of Bad Bugs, No Drugs: A Regulatory Perspective Using the Example of Bloodstream Infection as an Indication by Boucher, Helen W.

“…Bloodstream infections present many challenges to clinicians. The number of hospitalized patients with bloodstream infection continues to increase, and the…”
Get full text

Initial Low-Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic by Cosgrove, Sara E., Vigliani, Gloria A., Campion, Marilyn, Fowler, Vance G., Abrutyn, Elias, Corey, G. Ralph, Levine, Donald P., Rupp, Mark E., Chambers, Henry F., Karchmer, Adolf W., Boucher, Helen W.

“…Background.The safety of adding initial low-dose gentamicin to antistaphylococcal penicillins or vancomycin for treatment of suspected Staphylococcus aureus…”
Get full text

Screening of donor and candidate prior to solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice by Malinis, Maricar, Boucher, Helen W.

“…This updated section of the guideline from the Infectious Diseases Community of Practice of the American Society of Transplantation reviews the screening of…”
Get full text

Weekly SARS-CoV-2 screening of asymptomatic kindergarten to grade 12 students and staff helps inform strategies for safer in-person learning by Doron, Shira, Ingalls, Robin R., Beauchamp, Anne, Boehm, Jesse S., Boucher, Helen W., Chow, Linda H., Corridan, Linda, Goehringer, Katey, Golenbock, Doug, Larsen, Liz, Lussier, David, Testa, Marcia, Ciaranello, Andrea

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in K–12 schools was rare during in 2020–2021; few studies included Centers for…”
Get full text

Partial Oral Therapy for Osteomyelitis and Endocarditis — Is It Time? by Boucher, Helen W

“…Antimicrobial resistance threatens health and global security, with an estimated 162,000 deaths per year in the United States caused by multidrug-resistant…”
Get full text

New Antibiotics for Resistant Infections: What Happens After Approval? by Howard-Anderson, Jessica, Boucher, Helen W

Get full text

A Tribute to Dr Robert C. Moellering Jr (1937–2014) by Boucher, Helen W., MD, FACP, FIDSA

Get full text

Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process by Ison, Michael G, Wolfe, Cameron, Boucher, Helen W

Get full text

Antimicrobial Agents for Complicated Skin and Skin-Structure Infections: Justification of Noninferiority Margins in the Absence of Placebo-Controlled Trials by Spellberg, Brad, Talbot, George H., Boucher, Helen W., Bradley, John S., Gilbert, David, Scheld, W. Michael, Edwards, John, Bartlett, John G.

“…Background. The United States Food and Drug Administration requires clinical trial noninferiority margins to preserve a fraction (eg, 50%) of the established…”
Get full text

Disseminated mucormycosis masquerading as rejection early after orthotopic heart transplantation by Margoles, Lindsay, DeNofrio, David, Patel, Ayan R., Golan, Yoav, Vest, Amanda R., Arkun, Knarik, Boucher, Helen W., Kiernan, Michael S., Upshaw, Jenica N.

“…Mucorales organisms are an uncommon cause of invasive fungal infections after solid organ transplantation but are associated with great morbidity and…”
Get full text

Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward by Nanayakkara, Amila K., Boucher, Helen W., Fowler, Vance G., Jezek, Amanda, Outterson, Kevin, Greenberg, David E.

“…Infection is the second leading cause of death in patients with cancer. Loss of efficacy in antibiotics due to antibiotic resistance in bacteria is an urgent…”
Get full text

Is It Possible to Blind a Trial for Community-Acquired Pneumonia? by Boucher, Helen W.

“…Blinding a randomized, controlled clinical trial provides benefits on several levels but often is not perfectly executed or well described. Most recent…”
Get full text

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections by Motsch, Johann, Murta de Oliveira, Cláudia, Stus, Viktor, Köksal, Iftihar, Lyulko, Olexiy, Boucher, Helen W, Kaye, Keith S, File, Thomas M, Brown, Michelle L, Khan, Ireen, Du, Jiejun, Joeng, Hee-Koung, Tipping, Robert W, Aggrey, Angela, Young, Katherine, Kartsonis, Nicholas A, Butterton, Joan R, Paschke, Amanda

“…Abstract Background The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated…”
Get full text

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection by Boucher, Helen W, Wilcox, Mark, Talbot, George H, Puttagunta, Sailaja, Das, Anita F, Dunne, Michael W

“…Treatment of acute bacterial skin infection is becoming more complicated as antimicrobial resistance increases. In this trial of dalbavancin, a…”
Get full text

Associations between the Genotypes of Staphylococcus aureus Bloodstream Isolates and Clinical Characteristics and Outcomes of Bacteremic Patients by Lalani, Tahaniyat, Federspiel, Jerome J, Boucher, Helen W, Rude, Thomas H, Bae, In-Gyu, Rybak, Michael J, Tonthat, Giang T, Corey, G. Ralph, Stryjewski, Martin E, Sakoulas, George, Chu, Vivian H, Alder, Jeff, Steenbergen, Judith N, Luperchio, Steven A, Campion, Marilyn, Woods, Christopher W, Fowler, Vance G

“…We investigated associations between the genotypic and phenotypic features of Staphylococcus aureus bloodstream isolates and the clinical characteristics of…”
Get full text

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study) by Titov, Ivan, Wunderink, Richard G, Roquilly, Antoine, Rodríguez Gonzalez, Daniel, David-Wang, Aileen, Boucher, Helen W, Kaye, Keith S, Losada, Maria C, Du, Jiejun, Tipping, Robert, Rizk, Matthew L, Patel, Munjal, Brown, Michelle L, Young, Katherine, Kartsonis, Nicholas A, Butterton, Joan R, Paschke, Amanda, Chen, Luke F

“…Abstract Background Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant…”
Get full text